MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
DSIP Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
Delta Sleep Inducing Peptide (DSIP) is a nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) originally isolated by Schoenenberger and Monnier in 1977 from the cerebral venous blood of rabbits subjected to electrical stimulation of the intralaminar thalamic nuclei in patterns that induced slow-wave sleep. DSIP appears to modulate delta-wave activity on quantitative EEG without binding any single high-affinity receptor; proposed targets include GABAergic interneurons in the thalamic reticular nucleus, modulation of corticotropin-releasing hormone release at the hypothalamic-pituitary axis, and influence on endogenous opioid and somatostatin signaling. Researchers study it for insomnia with disrupted sleep architecture, opioid withdrawal symptoms, chronic pain syndromes with comorbid sleep fragmentation, stress-induced cortisol elevations, and as a research probe of slow-wave sleep neurophysiology. Mechanistic and small clinical work is summarized in PMID 6088100 (Schoenenberger 1984) and PMID 8521825 reviewing therapeutic applications in pain and sleep.
Reconstitute: Add 3 mL bacteriostatic water → 1.67 mg/mL concentration.
Easy measuring: At 1.67 mg/mL, 1 unit = 0.01 mL = 0.0167 mg (17 mcg) on a U-100 insulin syringe.
Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Plasma half-life: Extremely short, approximately 7 to 15 minutes after intravenous administration in humans, due to rapid peptidase cleavage. Effects on sleep architecture outlast plasma exposure by hours.
Onset: Subjective sedation and EEG delta-band changes have been described within 30 to 60 minutes of subcutaneous dosing in research subjects, with effects most apparent on sleep latency and slow-wave continuity.
Regulatory status: Not approved by FDA or EMA for any indication. Research use only; no large randomized placebo-controlled trials exist supporting routine clinical sleep use.
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake).
Inject slowly; wait a few seconds before withdrawing the needle.
Do not aspirate for subcutaneous injections; inject slowly and steadily[12].
Interactive DSIP Syringe Calculator
Currently visualizing the 5 mg vial reconstituted with 3 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 5mg dry powder in 3mL water yields 1.67 mg/mL. To evaluate a 250mcg dose, pull to 15.0 units (15 syringe ticks).
U-100 Syringe Representation
15.0 Units (15 Ticks)
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Week 1 | 100 mcg | 6 units (0.06 mL) |
| Week 2 | 150 mcg | 9 units (0.09 mL) |
| Week 3 | 200 mcg | 12 units (0.12 mL) |
| Weeks 4–8 | 250–300 mcg | 15–18 units (0.15–0.18 mL) |
Administration guidelines: Refer to guidelines | 3 mL Reconstitution
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Week 5 | 350–400 mcg | 21–24 units (0.21–0.24 mL) |
| Weeks 6–8+ | 400–500 mcg | 24–30 units (0.24–0.30 mL) |
Administration guidelines: Refer to guidelines | 3 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 5 mg vial.
Peptide Vials (DSIP, 5 mg each):
- check8 weeks at ~200 mcg/day avg ≈ 2–3 vials
- check12 weeks at ~200 mcg/day avg ≈ 3–4 vials
- check12 weeks at ~300 mcg/day avg ≈ 5–6 vials
Insulin Syringes (U-100):
- checkPer week: 7 syringes (1/day)
- check8 weeks: 56 syringes
- check12 weeks: 84 syringes
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- check3 vials: 9 mL → 1 × 10 mL bottle
- check5 vials: 15 mL → 2 × 10 mL bottles
- check6 vials: 18 mL → 2 × 10 mL bottles
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- checkPer week: 14 swabs (2/day)
- check8 weeks: 112 swabs → recommend 2 × 100-count boxes
- check12 weeks: 168 swabs → recommend 2 × 100-count boxes
Mechanism of Action (MOA)
DSIP is one of the small group of identified endogenous sleep-modulating peptides. Despite its name, DSIP does not function as a classical sedative-hypnotic; its effect on sleep is modest and emerges most clearly in subjects with disturbed sleep architecture rather than in healthy short-sleeping volunteers [4][6]. The molecular target has not been definitively identified. DSIP does not bind to GABA-A receptors, melatonin receptors, or adenosine receptors in any high-affinity manner, and its effects appear to be mediated indirectly through modulation of corticotropin-releasing hormone (CRH) tone, growth hormone-releasing hormone (GHRH) pulses, and the central noradrenergic system [3][7]. EEG recordings after synthetic DSIP administration in rabbits show a 35 percent increase in cortical delta activity and enhancement of sleep spindles, consistent with promotion of slow-wave sleep [1]. The peptide has a plasma half-life of only 5 to 15 minutes, but its effects on sleep architecture persist for days after a single dose, suggesting that DSIP triggers a downstream regulatory cascade rather than acting as a direct hypnotic at the moment of administration. Pharmacokinetic studies indicate that DSIP crosses the blood-brain barrier to a small but detectable degree, with peptide concentrations in cerebrospinal fluid following systemic injection rising approximately 10 to 20 percent above baseline [2]. Common research routes include subcutaneous and intramuscular injection 30 to 60 minutes before sleep, with a typical dose range of 100 to 500 mcg in adult research subjects. Some early protocols used intravenous infusions at 25 nmol/kg over 5 minutes; this route is rarely used outside controlled studies because it offers no clear advantage. Beyond sleep induction, DSIP has been investigated for effects on stress modulation (it reduces ACTH and cortisol responses to acute stressors in rodents) [8], opioid withdrawal (it attenuates withdrawal symptom intensity in small open-label studies), seizure thresholds (it has anticonvulsant activity in some animal models), and growth hormone release (it appears to increase nocturnal GH secretion modestly in association with deeper slow-wave sleep). Common research applications today include adjunctive use in stubborn insomnia not responsive to conventional therapy, jet lag and shift-work-related sleep disruption, athletic recovery protocols that aim to enhance slow-wave sleep depth, and exploratory work in opioid taper support. DSIP is typically cycled 5 to 14 nights per month rather than used continuously, both because tolerance has been described anecdotally and because the published evidence base does not support indefinite daily use. The peptide is sometimes paired in research protocols with growth hormone secretagogues such as ipamorelin or CJC-1295 on the rationale that deeper slow-wave sleep amplifies endogenous nocturnal GH pulsatility; this combination is mechanistically plausible but lacks formal pharmacokinetic interaction data. Critical caveats include the variability of inter-individual response (some subjects describe no detectable subjective effect even at the higher end of the dose range), the limited size of the historical clinical trial dataset (most published controlled studies have fewer than 30 subjects), and the absence of long-term safety data extending beyond several weeks of repeated dosing. Despite the modest evidence base, DSIP remains one of the few endogenous peptides identified as a sleep modulator with a defined nonapeptide sequence and a multi-decade preclinical pedigree.
Clinical Trial Efficacy Highlights
- starSchoenenberger, Monnier, and colleagues demonstrated that synthetic Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu increased cortical delta EEG activity by approximately 35 percent in recipient rabbits, replicating the effect of the natively isolated peptide and confirming the active sequence [1][2].
- starSchneider-Helmert and Schoenenberger administered 25 nmol/kg intravenous synthetic DSIP to six middle-aged chronic insomniacs and observed longer sleep duration, fewer awakenings, slightly increased REM sleep, and no daytime sedation, providing the foundational human data for sleep applications [5].
- starIn rats, DSIP enhanced slow-wave sleep and was correlated with increased sleep-related growth hormone secretion, suggesting a coupling between deep sleep promotion and somatotropic axis activation [3].
- starStudies of stress modulation in rats and humans have shown that DSIP administration reduces the ACTH and cortisol response to acute stressors, supporting an anxiolytic and stress-buffering effect distinct from its sleep action [7][8].
- starOpen-label observational work in opioid and alcohol withdrawal contexts has described reductions in subjective withdrawal symptom intensity and improved sleep quality during the acute taper phase, though no large randomized controlled trial has confirmed these effects [9].
- starDSIP exerts anticonvulsant activity in several rodent seizure models including pentylenetetrazole-induced and audiogenic seizures, raising research interest in its role as an endogenous antiepileptic modulator [6].
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningDSIP is generally well tolerated in the small published clinical studies, with no significant daytime sedation, hangover effect, or psychomotor impairment reported at standard research doses.
- warningInjection site reactions including mild erythema and transient discomfort are the most common local adverse events; no systemic hypersensitivity reactions have been reported in the published trial cohorts.
- warningSome users describe vivid dreaming or increased dream recall during the first few nights of use, presumably reflecting altered REM-NREM architecture; this is generally not distressing but can be undesirable for some research subjects.
- warningBecause DSIP modulates the hypothalamic-pituitary axis, theoretical risks include alteration of cortisol diurnal pattern, growth hormone secretion, and thyroid axis pulsatility; longitudinal safety data on these endpoints are sparse.
- warningTolerance has been anecdotally described with continuous nightly dosing, providing the rationale for cycling 5 to 14 nights per month rather than daily indefinite use.
- warningDrug-drug interactions have not been systematically characterized; concurrent use with conventional hypnotics, benzodiazepines, or opioids should be approached cautiously even though no pharmacokinetic or pharmacodynamic interactions are documented.
- warningUse in pregnancy, lactation, and pediatric populations has not been studied and is not recommended.
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical DSIP dosage?expand_more
Research protocols typically use 100 to 500 mcg subcutaneously or intramuscularly approximately 30 to 60 minutes before intended sleep onset, with cycles of 5 to 14 nights per month. Intravenous dosing at approximately 25 nmol/kg has been used in controlled studies but offers no practical advantage.
How is DSIP used in research protocols?expand_more
Investigations focus on stubborn insomnia, shift-work and jet-lag-related sleep disruption, athletic recovery protocols emphasizing slow-wave sleep, and adjunctive use during opioid or alcohol withdrawal. Endpoints include polysomnographic delta power, sleep efficiency, and validated insomnia scales.
Can DSIP be combined with other peptides?expand_more
DSIP is sometimes paired with growth hormone secretagogues such as ipamorelin or CJC-1295 on the rationale that deeper slow-wave sleep amplifies endogenous GH pulses. Formal pharmacokinetic interaction data are absent, and combination use is purely empirical.
What are the side effects of DSIP?expand_more
Most users report no significant adverse effects beyond mild injection site reactions and occasional vivid dreaming. Daytime sedation and hangover are notably absent. Long-term safety, hypothalamic-pituitary axis effects, and tolerance development remain poorly characterized.
Is DSIP FDA approved?expand_more
No. DSIP is not approved by the FDA, EMA, or other major Western regulators for any indication. It is not authorized as a drug, dietary supplement, or medical food and is used only in research contexts under physician supervision.
Academic References & Study Citations
Schoenenberger GA, Monnier M. Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proc Natl Acad Sci U S A. 1977;74(3):1282-1286. View Scientific Paper →
Schoenenberger GA. Characterization, properties and multivariate functions of delta-sleep-inducing peptide (DSIP). Eur Neurol. 1984;23(5):321-345. View Scientific Paper →
Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J Neurochem. 2006;97(2):303-309. View Scientific Paper →
Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): an update. Peptides. 1986;7(6):1165-1187. View Scientific Paper →
Schneider-Helmert D, Schoenenberger GA. Effects of DSIP on disturbed human sleep. Experientia. 1981;37(8):913-917. View Scientific Paper →
Yehuda S, Kastin AJ. Behavioral effects of DSIP and other peptides. Brain Res Bull. 1980;5(suppl 2):69-72. View Scientific Paper →
Iyer KS, McCann SM. Delta sleep inducing peptide (DSIP) influences the release of LH and prolactin in conscious ovariectomized rats. Brain Res Bull. 1987;19(5):535-538. View Scientific Paper →
Sudakov KV, Ivanov VT, Koplik EV, Vedyaev FP, Mikhaleva II, Sargsyan AS. Delta-sleep-inducing peptide (DSIP) as a factor facilitating animals' resistance to acute emotional stress. Pavlov J Biol Sci. 1983;18(1):1-5. View Scientific Paper →
Nakamura A, Nakashima M, Sakai K, Niwa M, Nozaki M, Shiomi H. Delta sleep-inducing peptide administered intracerebroventricularly inhibits naloxone-precipitated withdrawal signs in morphine-dependent rats. Eur J Pharmacol. 1989;160(1):105-112. View Scientific Paper →